how much cjc 1295: Frequently asked questions

Combining CJC-1295 no DAC with a growth hormone-releasing peptide (GHRP-2, GHRP-6, ipamorelin, or hexarelin) is standard practice in advanced research protocols. GHRH analogues and GHRPs act on different receptors. GHRH receptors on somatotrophs and ghrelin receptors on the same cells. Creating synergistic GH release. Research from Endocrinology found that co-administration of GHRH + GHRP-6 produced GH peaks 5–10× higher than either peptide alone, with the combination outperforming the sum of individual responses. Standard dosing: 100mcg CJC-1295 no DAC + 100–200mcg GHRP administered simultaneously, 2–3 times daily. Both peptides must be injected within the same 5-minute window to capture peak synergy.

Peptides are fragile molecules. Temperature excursions above 8°C accelerate degradation of the amino acid chain, particularly for GHRH analogues like CJC-1295. If reconstituted CJC-1295 was left unrefrigerated for 8–12 hours, it's likely partially denatured but not completely inactive. The challenge is you can't visually assess potency loss. The solution will appear clear and unchanged even if 30–50% of the active peptide has degraded. Our recommendation: do not use peptide that's been unrefrigerated overnight for research where precise dosing matters. The cost of replacing a 5mg vial is lower than the cost of running a protocol on compromised compound. For lyophilised powder (unreconstituted), brief room temperature exposure (24–48 hours) is less critical. Return it to −20°C storage immediately.

Flushing and mild headache are vasodilatory effects mediated by nitric oxide release downstream of GHRH receptor activation. They're physiological responses, not allergic reactions. These effects typically resolve within 20–40 minutes and diminish with repeated dosing as the body adapts. If symptoms are severe or persistent, reduce the dose by 25–50% for one week before re-escalating. Injecting on an empty stomach can intensify vasodilatory effects; administering the peptide 30–60 minutes after a small meal containing healthy fats often reduces symptom severity.

Administer the missed dose as soon as you remember, then resume your regular schedule from that new injection date. CJC-1295 with DAC maintains elevated GH levels for 6–8 days, so a three-day delay means you're still within the therapeutic window. Plasma concentration has declined but not to baseline. Missing an injection by more than five days (past the half-life window) requires restarting the loading phase at a conservative dose (100–200mcg) to avoid acute receptor overstimulation after a clearance period. For non-DAC formulations, missing a single daily dose has minimal impact; resume the next scheduled injection without compensatory dosing.

Stop the daily protocol immediately and calculate total peptide administered over the accidental dosing period. If you've been micro-dosing (e.g., 50mcg daily for seven days), you've administered 350mcg total. Roughly equivalent to a single high-end weekly dose, but fragmented across time in a way that prevented stable plasma elevation. Resume the correct protocol: administer the intended weekly dose (200–300mcg) and schedule the next injection 7 days later. The albumin-bound DAC modification means prior micro-doses are still circulating but at subtherapeutic levels; you won't double-dose by resuming the correct schedule. Monitor for injection site reactions, as compressed dosing timelines can increase localised inflammation.

Skip the missed dose and continue with your next scheduled injection at the planned time. Do not double-dose to 'catch up'. GHRH receptor saturation doesn't scale proportionally with dose, and excessively large single injections increase the risk of side effects (flushing, headache, transient hypoglycaemia) without meaningfully increasing GH output. Missing a single injection in a multi-dose protocol reduces that day's total GH elevation but doesn't compromise long-term outcomes. Missing multiple consecutive doses over 48–72 hours may require restarting at a lower dose to re-establish tolerance if initial injections caused side effects during titration.